Koo,

I haven't heard anything new on apabetalone and facioscapulohumeral muscular dystrophy (FSHD). I am assuming that Resverlogix is still exploring the potential for apabetalone or similar BET inhibitor for FSHD with pre-clinical studies. So there is no evidence that apabetalone is out of the picture. Hopefully they give an update on this at the AGM/Corporate Update on Wednesday. If not, good question for the Q&A. 

My biggest question is, how much apabetalone reaches the muscle tissue via oral dosing? Resverlogix has observed/disclosed effects in liver, kidney and vasculature, as well as brain (though this may be an indirect effect of apabetalone). I'm not sure how much orally administered apabetalone reaches the muscle. They may need to optimize a different drug delivery method for apabetalone to increase the muscle exposure. The publication using apabetalone and BET inhibitors to potential FSHD therapy was using patient derived skeletal muscle cell cultures. Cell culture is easy to get drug exposure. Not as easy to get to muscle tissue with oral dosing in an animal/human. 

BearDownAZ